PRECIGEN Investors

Press & Events

Press & Events

Press Releases

Displaying 1 - 10 of 25

Upcoming Events

Past Events

Aug 10, 2020 at 4:30 PM EDT
Precigen will host a conference call to discuss the results and provide a general business update.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 6003292 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may also access the live webcast through Precigen’s website at the link below.
Read More
Jun 22, 2020

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “PRGN-3005 UltraCAR-T™: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer”. (Abstract 6593)

Read More
May 06, 2020 at 4:15 PM EDT
Precigen will host a conference call to discuss the results and provide a general business update.

The conference call may be accessed by dialing 1-833-646-0488 (US/Canada toll-free) or 1-918-922-6615 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may also access the live webcast through Precigen’s website at the link below.
Read More
Mar 02, 2020 at 5:30 PM EST
Precigen will host a conference call to discuss the results and provide a general business update.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1 412-317-6061 (International) and providing the number 4230814 to join the Precigen Conference Call.
Read More
Dec 08, 2019 at 6:00 PM EST

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “Preclinical Characterization of PRGN-3006 UltraCAR-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer.” (Abstract #2660)

Orlando, FL
Read More
Media Kit

Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:

press@precigen.com

Download
Media Kit